

# Normalization of Organ-on-a-Chip Samples for Mass Spectrometry Based Proteomics and Metabolomics via Dansylation Assay

Erin M. Gallagher<sup>1</sup>, Gabrielle M. Rizzo<sup>1</sup>, Russell Dorsey<sup>1</sup>, Elizabeth S. Dhumakupt<sup>1</sup>, Theodore S. Moran<sup>1</sup>, Phillip M. Mach<sup>1,2</sup>, Conor C. Jenkins<sup>1</sup>


<sup>1</sup>U.S. Army Combat Capabilities Development Command Chemical Biological Center, Aberdeen Proving Ground, MD, <sup>2</sup>BioSciences Division, B11 Bioenergy and Biome Sciences, Los Alamos National Laboratory, Los Alamos, NM

## Abstract





Lab-on-a-chip technology has rapidly expanded and has been made even more powerful with the use of mass spectrometry-based multi-omics analysis, which is well suited for the sample-limited nature of the lab-on-a-chip format. In our research, organ-on-a-chip technology allows us to achieve high-throughput experimentation without the use of model organisms, while simultaneously permitting us to focus on organ and sub-organ systems. However, chip-to-chip variability in analysis of the proteome and metabolome can mask true biological changes that occur within the system. While this variability could be conquered via increasing N, doing so also increases cost and labor. We instead sought to improve our normalization methods to circumvent this issue.

Here we utilize a CNBio liver chip to investigate mechanisms of action, toxicity, and host response following exposure to VX. To combat chip-to-chip variations, we developed a method for analysis and normalization of the CNBio liver chip, using dansylation and BCA assays to achieve normalization of both the metabolome and proteome. This strategy resulted in reduced variation effects, allowing us to draw more statistically confident conclusions and observe trends that were a result of experimental conditions and not of systemic chip-to-chip variations. This method can easily be expanded to multiomics analysis of other organs-on-a-chip.

## Methods



## Results & Discussion



## Conclusions

Organ-on-a-chip systems are an invaluable tool in Defense research. They allow for more precise understanding of the cellular effects of toxins, environmental hazards, or other potential threats a Warfighter could encounter, and are a cost effective and higher throughput solution to using model organisms. However, in order to achieve more conclusive results from these samples, normalization strategies should be employed. We found that normalizing metabolomic samples prior to data acquisition decreased CV values of control samples by more than two-fold in the 0-50 range. This led to identification of more significantly changing metabolites that could elucidate metabolic pathways affected by VX exposure. Similarly, normalized proteomic data identified proteins relevant to biochemical functions affected by VX. Finally, when normalized proteomic and metabolomic data are brought together, a more accurate picture of VX exposure emerges as demonstrated by the joint pathway enrichment. More than 80 pathways were identified as significant in the normalized data set that point to more specific effects of VX on the cell population, rather than the non-specific systems that were deemed significant in the unnormalized data.

**Acknowledgements:** This research was performed while E.M.G. held a NRC Post-Doctoral Research Associateship Award at DEVCOM CBC. The authors would like to acknowledge Drs. Kyle Glover and Jennifer Sekowski for their scientific contributions on the RTA-MPS project. Funding for this project was provided by the Defense Advanced Research Projects Agency (DARPA) and the Defense Threat Reduction Agency-Joint Science and Technology Office (DTRA-JSTO) for Chemical and Biological Defense.



DEVCOM CBC @ DTRA CBD S&T Conference

Scan the QR Code to view all of CBC's  
2022 DTRA CBD S&T Conference materials  
<https://cbc.devcom.army.mil/cbdst-conference/>